| Basics |
Verastem, Inc.
Verastem Inc is a biopharmaceutical company engaged in discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates include duvelisib and defactinib.
|
| IPO Date: |
February 1, 2012 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$468.17M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.17 | 3.38%
|
| Avg Daily Range (30 D): |
$0.35 | 5.03%
|
| Avg Daily Range (90 D): |
$0.26 | 4.19%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.16M |
| Avg Daily Volume (30 D): |
1.75M |
| Avg Daily Volume (90 D): |
1.13M |
| Trade Size |
| Avg Trade Size (Sh.): |
277 |
| Avg Trade Size (Sh.) (30 D): |
111 |
| Avg Trade Size (Sh.) (90 D): |
115 |
| Institutional Trades |
| Total Inst.Trades: |
462 |
| Avg Inst. Trade: |
$1.88M |
| Avg Inst. Trade (30 D): |
$1.21M |
| Avg Inst. Trade (90 D): |
$1.8M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.18M |
| Avg Closing Trade (30 D): |
$.93M |
| Avg Closing Trade (90 D): |
$.88M |
| Avg Closing Volume: |
97.82K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-3.42
|
$-.96
|
$-1.55
|
|
Diluted EPS
|
$-3.42
|
$-.96
|
$-1.55
|
|
Revenue
|
$ 10M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -148.88M
|
$ -52.1M
|
$ -64.55M
|
|
Operating Income / Loss
|
$ -131.07M
|
$ -44.17M
|
$ -31.59M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 6.47M
|
$ M
|
$ -24.36M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jun 01, 2023:
1:12
|
|
